NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $0.85 -0.07 (-7.59%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Assertio Stock (NASDAQ:ASRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Assertio alerts:Sign Up Key Stats Today's Range$0.82▼$0.9750-Day Range$0.85▼$1.3552-Week Range$0.73▼$1.80Volume1.70 million shsAverage Volume932,166 shsMarket Capitalization$81.23 millionP/E RatioN/ADividend YieldN/APrice Target$3.25Consensus RatingBuy Company OverviewAssertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Read More… Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Assertio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks45th Percentile Overall ScoreASRT MarketRank™: Assertio scored higher than 45% of companies evaluated by MarketBeat, and ranked 677th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has received no research coverage in the past 90 days.Read more about Assertio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.17) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.39% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.39% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment-0.03 News SentimentAssertio has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Assertio this week, compared to 3 articles on an average week.Search Interest12 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows7 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Stock News HeadlinesAssertio Therapeutics (ASRT) Receives a Buy from Lake StreetNovember 13 at 1:40 AM | markets.businessinsider.comAssertio Holdings price target lowered to $2.15 from $2.75 at Alliance GlobalNovember 13 at 1:40 AM | markets.businessinsider.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 13, 2024 | Crypto Swap Profits (Ad)Assertio calls short-seller claims about accounting practices ‘false, baseless’November 12 at 11:58 AM | markets.businessinsider.comAssertio stock gains amid Q3 earnings, clash with activist investorNovember 12 at 11:58 AM | msn.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Call TranscriptNovember 12 at 11:58 AM | msn.comAssertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call TranscriptNovember 11 at 7:06 PM | seekingalpha.comAssertio Reports Third Quarter 2024 Financial ResultsNovember 11 at 4:02 PM | globenewswire.comSee More Headlines ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $1.07 at the start of the year. Since then, ASRT stock has decreased by 20.4% and is now trading at $0.8520. View the best growth stocks for 2024 here. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) posted its earnings results on Monday, November, 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The firm had revenue of $29.20 million for the quarter, compared to analyst estimates of $29.29 million. Assertio had a positive trailing twelve-month return on equity of 4.88% and a negative net margin of 261.08%. Who are Assertio's major shareholders? Assertio's top institutional shareholders include Empowered Funds LLC (0.45%), Palumbo Wealth Management LLC (0.20%), GSA Capital Partners LLP (0.16%) and Thurston Springer Miller Herd & Titak Inc. (0.05%). Insiders that own company stock include Daniel A Peisert, William Mckee, Heather L Mason, Jeff L Vacirca, Ajay Patel, Sam Schlessinger and Paul Schwichtenberg. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID). Company Calendar Last Earnings8/07/2024Today11/12/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$3.25 High Stock Price Target$4.00 Low Stock Price Target$2.75 Potential Upside/Downside+281.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-331,940,000.00 Net Margins-261.08% Pretax Margin-203.27% Return on Equity4.88% Return on Assets2.37% Debt Debt-to-Equity Ratio0.29 Current Ratio1.93 Quick Ratio1.51 Sales & Book Value Annual Sales$152.07 million Price / Sales0.53 Cash Flow$0.73 per share Price / Cash Flow1.17 Book Value$1.46 per share Price / Book0.58Miscellaneous Outstanding Shares95,340,000Free Float92,285,000Market Cap$81.23 million OptionableOptionable Beta0.83 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ASRT) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.